Abstract | OBJECTIVE: METHODS: Serum samples were tested from 65 patients with intestinal biopsy proven celiac disease, from 10 patients with Crohn's disease, and from 150 healthy blood donors. RESULTS: Human transglutaminase ELISA identified 64 of 65 celiac patients, whereas the guinea pig transglutaminase ELISA and IgA antiendomysium antibodies identified 58 of 65 and 60 of 65 subjects, respectively. The three tests showed comparable specificity. CONCLUSIONS: These results proved that the human tissue transglutaminase-based ELISA represents a cost-effective strategy for identifying both symptomatic and atypical forms of celiac disease and could mean that intestinal biopsy need no longer be the gold standard for diagnosing this clinical condition. Furthermore, early identification and treatment of patients with celiac disease in an outpatient setting could have significant implications for reducing long-term morbidity and can produce major savings in future health care costs.
|
Authors | D Sblattero, I Berti, C Trevisiol, R Marzari, A Tommasini, A Bradbury, A Fasano, A Ventura, T Not |
Journal | The American journal of gastroenterology
(Am J Gastroenterol)
Vol. 95
Issue 5
Pg. 1253-7
(May 2000)
ISSN: 0002-9270 [Print] United States |
PMID | 10811336
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Autoantibodies
- Immunoglobulin A
- Recombinant Proteins
- Transglutaminases
|
Topics |
- Adolescent
- Adult
- Animals
- Autoantibodies
(blood)
- Celiac Disease
(diagnosis)
- Child
- Child, Preschool
- Crohn Disease
(immunology)
- Enzyme-Linked Immunosorbent Assay
- Female
- Guinea Pigs
- Humans
- Immunoglobulin A
(blood)
- Male
- Middle Aged
- Muscle Fibers, Skeletal
(immunology)
- Recombinant Proteins
(immunology)
- Sensitivity and Specificity
- Transglutaminases
(immunology)
|